Eman A. Hamad

Prof. Dr. Eman A. Hamad

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2019 in JCI Insight
Verified
Journal Article
Closed access
PDF file
LGLaurel A. Grisanti
Laurel A. Grisanti
Claudio De LuciaClaudio De Lucia
Claudio De Lucia
TTToby P. Thomas
Toby P. Thomas
ASAron Stark
Aron Stark
JSJohn T. Strony
John T. Strony
DTDouglas G. Tilley
Douglas G. Tilley
Following injury, leukocytes are released from hematopoietic organs and migrate to the site of damage to regulate tissue inflammation and repair; however, leukocytes lacking β 2 -adrenergic receptor (β 2 -AR) expression have marked impairments in these processes. Beta blockade is a common strategy for the treatment of many cardiovascular etiologies; therefore, the objective of our study was to assess the impact of prior beta blocker treatment on baseline leukocyte parameters and their responsiveness to acute injury. In a temporal and β-adrenergic receptor isoform–dependent manner, chronic beta blocker infusion increased splenic vascular cell adhesion molecule 1 expression and leukocyte accumulation (monocytes/macrophages, mast cells, and neutrophils) and decreased chemokine receptor 2 (CCR2) expression and migration of bone marrow and peripheral blood leukocytes (PBLs) to, as well as infiltration into, the heart following acute cardiac injury. Further, CCR2 expression and migratory responsiveness were significantly reduced in the PBLs of patients receiving beta blocker therapy compared with beta blocker–naive patients. These results highlight the ability of chronic beta blocker treatment to alter baseline leukocyte characteristics that decrease leukocytes’ responsiveness to acute injury and suggest that prior beta blockade may act to reduce the severity of innate immune responses.

1 July 2019 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
MGMichael M. Givertz
Michael M. Givertz
EDErsilia M. DeFilippis
Ersilia M. DeFilippis
MCMonica Colvin
Monica Colvin
CDChad E. Darling
Chad E. Darling
TETonya Elliott
Tonya Elliott
MBMark Bonnell
Mark Bonnell

1 June 2020 in Transplant Immunology
Verified
Journal Article
Closed access
OTOlga A. Timofeeva
Olga A. Timofeeva
RARene Alvarez
Rene Alvarez
JPJustin Pelberg
Justin Pelberg
EYEdward Yoon
Edward Yoon
MAMohamed Alsammak
Mohamed Alsammak
EHEman A. Hamad
Eman A. Hamad

26 October 2021
Verified
Book Chapter
Closed access
PDF file
JHJamael Hoosain
Jamael Hoosain
EHEman A. Hamad
Eman A. Hamad

1 August 2023 in Clinical Cardiology
Verified
Journal Article
Open access
EHEman A. Hamad
Eman A. Hamad
MBMirnela Byku
Mirnela Byku
SLSharon B. Larson
Sharon B. Larson
FBFilio Billia
Filio Billia
The management of chronic heart failure over the past decade has witnessed tremendous strides in medical optimization and device therapy including the use of left ventricular assist devices (LVAD). What we once thought of as irreversible damage to the myocardium is now demonstrating signs of reverse remodeling and recovery. Myocardial recovery on the structural, molecular, and hemodynamic level is necessary for sufficient recovery to withstand explant and achieve sustained recovery post‐LVAD. Guideline‐directed medical therapy and unloading have been shown to aid in recovery with the potential to successfully explant the LVAD. This review will summarize medical optimization, assessment for recovery, explant methodologies and outcomes post‐recovery with explant of durable LVAD.

7 December 2023 in Current Heart Failure Reports
Verified
Journal Article
Closed access
PDF file
RRRoopa A. Rao
Roopa A. Rao
ABAnju Bhardwaj
Anju Bhardwaj
MMMrudula Munagala
Mrudula Munagala
SASonu Abraham
Sonu Abraham
SASanjana Adig
Sanjana Adig
EHEman A. Hamad
Eman A. Hamad